Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Vomiting 14Nausea 11Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma 3Lymphoma, Non-Hodgkin 2Leukemia 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Solid Tumours 1Sezary Syndrome 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Papillomavirus Infections 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

AZD 6244 5GSK 1363089 3pazopanib 1ispinesib 1Topotecan 1SLC-0111 1Rifampin 1Omeprazole 1Moxifloxacin 1Midazolam 1Itraconazole 1Granisetron 1Fluconazole 1Famotidine 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP1A2 1Carboplatin 1Carbon-14 1Caffeine 1BGC945 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumours × Granisetron × Clear all
NCT03333824 2019-03-25

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
33 enrolled
Other solid neoplasm

Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡